Based on ratings from 21 stock analysts, the Vertex Pharmaceuticals Inc stock price is expected to increase by 2.62% in 12 months. This is calculated by using the average 12-month stock price forecast for Vertex Pharmaceuticals Inc. The lowest target is $325.00 and the highest is $559.00. Please note analyst price targets are not guaranteed and could be missed completely.
Vertex Pharmaceuticals Inc has a total of 21 Wall St Analyst ratings. There are 13 buy ratings, 6 ratings, and 2 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Vertex Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
whitney ijem Canaccord Genuity | Sell | $371.0 | maintained | Feb 7, 2024 |
christopher raymond Piper Sandler | Buy | $450.0 | rated | Feb 6, 2024 |
naz rahman Maxim Group | Hold | None | initiatedcoverage | Feb 6, 2024 |
brian skorney Robert W. Baird | Sell | $325.0 | maintained | Feb 6, 2024 |
myles minter William Blair | Buy | None | maintained | Feb 6, 2024 |
geoff meacham Bank of America Securities | Buy | $540.0 | maintained | Feb 5, 2024 |
brian abrahams RBC Capital | Hold | $420.0 | rated | Feb 5, 2024 |
phil nadeau TD Cowen | Buy | $450.0 | maintained | Feb 5, 2024 |
evan seigerman BMO Capital | Buy | $480.0 | rated | Feb 5, 2024 |
olivia brayer Cantor Fitzgerald | Buy | $440.0 | initiatedcoverage | Feb 5, 2024 |
william pickering Bernstein | Hold | $450.0 | downgraded | Feb 2, 2024 |
hartaj singh Oppenheimer | Buy | $500.0 | rated | Jan 31, 2024 |
salveen richter Goldman Sachs | Buy | $559.0 | maintained | Jan 31, 2024 |
mohit bansal Wells Fargo | Buy | $500.0 | rated | Jan 30, 2024 |
joseph stringer Needham | Hold | None | maintained | Jan 30, 2024 |
david risinger Leerink Partners | Buy | None | reiterated | Jan 7, 2024 |
liisa bayko Evercore ISI | Buy | $436.0 | maintained | Jan 5, 2024 |
jasper hellweg Argus Research | Buy | $420.0 | maintained | Jan 4, 2024 |
terence flynn Morgan Stanley | Hold | $368.0 | maintained | Dec 28, 2023 |
debjit chattopadhyay Guggenheim | Buy | $445.0 | maintained | Dec 21, 2023 |
In 2023, VRTX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that VRTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
SPLK-USD
$154.42
TEAM-USD
$216.17
$42.33
TXN-USD
$162.4
TXG-USD
$49.11
TWKS-USD
$4.41